中文 | English
Return
Total: 10 , 1/1
Show Home Prev Next End page: GO
Author:(Xiaoxi LV)

1.Management of abdominal aortic aneurysm in young adult

Xiaoxi LI ; Shengming WANG ; Songqi LI ; Weiming LV ; Yongjie LIN ;

Chinese Journal of General Surgery 2000;0(11):-

2.A study on“one-stop”premarital healthcare services based on SWOT analysis

Xiaoxi LIU ; Jiannan LV ; Fang WANG ; Xue DING ; Ting YANG ; Qiuxia SONG ; Li SONG ; Ying LIU

Chinese Journal of Health Policy 2016;9(5):13-18

3.A ESI-based analysis ofhot literatures on pharmacology & toxicology

Xia WANG ; Chuanlu LV ; Xiaoxi SUN

Journal of Pharmaceutical Practice 2016;34(5):437-440

4.Simultaneous detection of 34 emerging contaminants in tap water by HPLC-MS/MS and health risk assessment

Yixuan CAO ; Ziwei YUAN ; Xiaoxi MU ; Chenshan LV ; Haiyan CUI ; Tao WANG ; Zhiwen WEI ; Zhongbing CHEN ; Hongyan ZOU ; Keming YUN ; Meng HU

Chinese Journal of Forensic Medicine 2024;39(1):31-38

5.Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm.

Huimin YAN ; Bing CUI ; Xiaowei ZHANG ; Xiaoming FU ; Jun YAN ; Xiaoxing WANG ; Xiaoxi LV ; Zhong CHEN ; Zhuowei HU

Acta Pharmaceutica Sinica B 2015;5(3):176-187

6.1,25-Dihydroxyvitamin D3 protects obese rats from metabolic syndrome promoting regulatory T cell-mediated resolution of inflammation.

Wen JIN ; Bing CUI ; Pingping LI ; Fang HUA ; Xiaoxi LV ; Jichao ZHOU ; Zhuowei HU ; Xiaowei ZHANG

Acta Pharmaceutica Sinica B 2018;8(2):178-187

7.TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2.

Xiaoxi LV ; Shanshan LIU ; Chang LIU ; Yunxuan LI ; Tingting ZHANG ; Jie QI ; Ke LI ; Fang HUA ; Bing CUI ; Xiaowei ZHANG ; Yuxin LIU ; Jiaojiao YU ; Jinmei YU ; Li LI ; Xia LI ; Zhigang YAO ; Bo HUANG

Acta Pharmaceutica Sinica B 2023;13(4):1631-1647

8.The cell cycle inhibitor P21 promotes the development of pulmonary fibrosis by suppressing lung alveolar regeneration.

Xiaoxi LV ; Chang LIU ; Shanshan LIU ; Yunxuan LI ; Wanyu WANG ; Ke LI ; Fang HUA ; Bing CUI ; Xiaowei ZHANG ; Jiaojiao YU ; Jinmei YU ; ZhuoWei HU

Acta Pharmaceutica Sinica B 2022;12(2):735-746

9.S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung.

Mengyao HAO ; Rong FU ; Jun TAI ; Zhenhuan TIAN ; Xia YUAN ; Yang CHEN ; Mingjin WANG ; Huimin JIANG ; Ming JI ; Fangfang LAI ; Nina XUE ; Liping BAI ; Yizhun ZHU ; Xiaoxi LV ; Xiaoguang CHEN ; Jing JIN

Acta Pharmaceutica Sinica B 2023;13(3):1110-1127

10.TRIB3‒GSK-3

Shanshan LIU ; Xiaoxi LV ; Xupeng WEI ; Chang LIU ; Qiao LI ; Jiali MIN ; Fang HUA ; Xiaowei ZHANG ; Ke LI ; Pingping LI ; Yang XIAO ; Zhuowei HU ; Bing CUI

Acta Pharmaceutica Sinica B 2021;11(10):3105-3119

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 10 , 1/1 Show Home Prev Next End page: GO